These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1273 related articles for article (PubMed ID: 33580175)

  • 1. Immunoreactive peptide maps of SARS-CoV-2.
    Mishra N; Huang X; Joshi S; Guo C; Ng J; Thakkar R; Wu Y; Dong X; Li Q; Pinapati RS; Sullivan E; Caciula A; Tokarz R; Briese T; Lu J; Lipkin WI
    Commun Biol; 2021 Feb; 4(1):225. PubMed ID: 33580175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients.
    Tornesello AL; Botti C; Micillo A; Labonia F; Arpino S; Isgrò MA; Meola S; Russo L; Cavalcanti E; Sale S; Nicastro C; Atripaldi L; Starita N; Cerasuolo A; Reimer U; Holenya P; Buonaguro L; Buonaguro FM; Tornesello ML
    J Transl Med; 2023 Feb; 21(1):123. PubMed ID: 36788606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
    Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities.
    Imai K; Matsuoka M; Tabata S; Kitagawa Y; Nagura-Ikeda M; Kubota K; Fukada A; Takada T; Sato M; Noguchi S; Takeuchi S; Arakawa N; Miyoshi K; Saito Y; Maeda T
    Int J Infect Dis; 2021 Oct; 111():68-75. PubMed ID: 34407480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity.
    Guzmán-Martínez O; Guardado K; Varela-Cardoso M; Trujillo-Rivera A; Gómez-Ñañez I; Ortiz-León MC; Espinosa R; Ramos C; Pérez-Carreón JI; López-Guerrero DV; Sampieri CL; Alanís-García AB; Rojas-Durán F; Zenteno-Cuevas R; Gutiérrez M; Montero H
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.
    Kubota-Koketsu R; Terada Y; Yunoki M; Sasaki T; Nakayama EE; Kamitani W; Shioda T
    Transfusion; 2021 Feb; 61(2):356-360. PubMed ID: 33104267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa.
    Tso FY; Lidenge SJ; Peña PB; Clegg AA; Ngowi JR; Mwaiselage J; Ngalamika O; Julius P; West JT; Wood C
    Int J Infect Dis; 2021 Jan; 102():577-583. PubMed ID: 33176202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses.
    Petrie JG; Bazzi LA; McDermott AB; Follmann D; Esposito D; Hatcher C; Mateja A; Narpala SR; O'Connell SE; Martin ET; Monto AS
    J Infect Dis; 2021 Jul; 224(1):49-59. PubMed ID: 33755731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Application of Human Coronavirus Protein Microarray for Specificity Analysis.
    Du PX; Chou YY; Santos HM; Keskin BB; Hsieh MH; Ho TS; Wang JY; Lin YL; Syu GD
    Anal Chem; 2021 Jun; 93(21):7690-7698. PubMed ID: 34011150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully automated detection and differentiation of pandemic and endemic coronaviruses (NL63, 229E, HKU1, OC43 and SARS-CoV-2) on the hologic panther fusion.
    Cordes AK; Rehrauer WM; Accola MA; Wölk B; Hilfrich B; Heim A
    J Med Virol; 2021 Jul; 93(7):4438-4445. PubMed ID: 33350484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoinformatics prediction of potential immunodominant epitopes from human coronaviruses and association with autoimmunity.
    Mathew S; Fakhroo AD; Smatti M; Al Thani AA; Yassine HM
    Immunogenetics; 2022 Apr; 74(2):213-229. PubMed ID: 35006282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity.
    Lehmann AA; Kirchenbaum GA; Zhang T; Reche PA; Lehmann PV
    Front Immunol; 2021; 12():635942. PubMed ID: 34127926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etiology and clinical characteristics of SARS-CoV-2 and other human coronaviruses among children in Zhejiang Province, China 2017-2019.
    Zhang Y; Su L; Chen Y; Yu S; Zhang D; Mao H; Fang L
    Virol J; 2021 Apr; 18(1):89. PubMed ID: 33931105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of Coronavirus and SARS-CoV-2.
    Malik YA
    Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63.
    Saletti G; Gerlach T; Jansen JM; Molle A; Elbahesh H; Ludlow M; Li W; Bosch BJ; Osterhaus ADME; Rimmelzwaan GF
    Sci Rep; 2020 Dec; 10(1):21447. PubMed ID: 33293664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients.
    Schwarz T; Heiss K; Mahendran Y; Casilag F; Kurth F; Sander LE; Wendtner CM; Hoechstetter MA; Müller MA; Sekul R; Drosten C; Stadler V; Corman VM
    Front Immunol; 2021; 12():629185. PubMed ID: 33833755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCoV-NL63 and SARS-CoV-2 Share Recognized Epitopes by the Humoral Response in Sera of People Collected Pre- and during CoV-2 Pandemic.
    Simula ER; Manca MA; Jasemi S; Uzzau S; Rubino S; Manchia P; Bitti A; Palermo M; Sechi LA
    Microorganisms; 2020 Dec; 8(12):. PubMed ID: 33327507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
    Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
    J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
    Dalakas MC; Bitzogli K; Alexopoulos H
    Front Immunol; 2021; 12():627285. PubMed ID: 33679770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 64.